Fixed Elranatamab Dosing Maintains Safety and Efficacy Across Patient Body Weights
A study of the MagnetisMM-3 trial reveals that fixed-dose elranatamab maintains consistent pharmacokinetics, safety, and response rates across diverse patient ...
A study of the MagnetisMM-3 trial reveals that fixed-dose elranatamab maintains consistent pharmacokinetics, safety, and response rates across diverse patient ...
Results from the randomized phase II ImmunoPRISM trial demonstrate that the bispecific T cell engager teclistamab achieves high rates of ...
A systematic review and index case report reveal that bispecific antibody treatments for relapsed multiple myeloma carry a rare but ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.